Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer

Provision of computational biology support for research by Melbourne Bioinformatics, MDHS, UoM to A/Prof Scott's lab of the Walter and Eliza Hall Institute of Medical Research.